Phase 2 Myasthenia Gravis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are a man or woman aged 18 or older at the time of signing the consent form
- You have been diagnosed with Myasthenia Gravis (MG) at a moderate to severe level (classified as MGFA class II, III, or IV)
- You have had a blood test that confirmed the presence of specific antibodies linked to MG (called AChR or MuSK antibodies)
- You are able to swallow tablets
- Your body weight and height fall within a healthy range (BMI between 18 and 35), and you weigh at least 40 kg (about 88 lbs)
- You are willing and able to use an appropriate method of contraception during the study, as required by local guidelines
- You are able to understand the study and have given your signed agreement to take part
Who may not be able to join:
- You have a known physical or mental health condition that, in the doctor's opinion, could affect your safe participation or make it harder to assess the results
- You have other significant health or lab test findings that could interfere with how the study is run or its results
- You have taken part in another clinical trial or received an experimental treatment within the past 30 days (or longer, depending on the medication involved)
- You have a history of not following or sticking to your MG treatment as prescribed
- You are currently pregnant, breastfeeding, or planning to become pregnant during the study (for female participants)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: contact@nmdpharma.com
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from baseline to day 21 in QMG total score for NMD670 vs placebo
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.